IE
TSHA icon

Israel Englander’s Taysha Gene Therapies TSHA Stock Holding History

Israel Englander’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-220,000
Closed -$719K – 6467
2025
Q3 		$719K Buy
+220,000
New +$623K ﹤0.01% 4855
2024
Q2 		– Sell
-150,000
Closed -$431K – 6551
2024
Q1 		$431K Buy
+150,000
New +$313K ﹤0.01% 4914

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Israel Englander's TSHA Position: Q2 2026 in Review

Israel Englander reduced its Taysha Gene Therapies (TSHA) stake by 35% in Q2 2026, selling an estimated $6.83M and leaving 2,126,838 shares worth $14.5M. The position accounts for 0.01% of the portfolio, ranked #1933.

Israel Englander first reported a position in TSHA in Q3 2020 and has held it in 20 quarters since. The position peaked at $17.5M in Q4 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Israel Englander held 2,126,838 shares of Taysha Gene Therapies worth $14.5M as of Q2 2026.
  • Israel Englander sold 1,154,982 Taysha Gene Therapies shares in Q2 2026, an estimated $6.83M.
  • Taysha Gene Therapies made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1933 holding.
  • Israel Englander first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 20 quarters since.
  • Israel Englander's Taysha Gene Therapies position peaked at $17.5M in Q4 2025.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.